The city of Milwaukee Health Department shared some of its results from this past weekend's lead testing clinic at Bradley ...

Weber said lead issues at MPS schools aren't going away, noting a lot of buildings have not been maintained and have chipping ...

Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...

The market is poised for exponential growth with rising awareness, early diagnosis, and increasing investments in rare disease research. Mucopolysaccharidosis (MPS) is a group of rare genetic ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku.

US biotech Regenxbio (Nasdaq: RGNX) has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) ...

A primary growth driver for the Mepsevii market is the rising prevalence of mucopolysaccharidosis (MPS) disorders. These genetic conditions stem from enzyme deficiencies, preventing the proper ...

Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...